Results 191 to 200 of about 60,113 (306)

Novel approaches for drug development against chronic primary pain: A systematic review

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus   +5 more
wiley   +1 more source

Novel Histopathologic Features of Diffuse Blue‐Gray Hyperpigmentation Associated With Kratom Use: A Case Report and Literature Review

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Background Drug‐induced hyperpigmentation accounts for 10%–20% of acquired pigmentary disorders and can be misdiagnosed for other causes such as melasma, post inflammatory changes, or heavy metal deposition. Kratom (Mitragyna speciosa), a Southeast Asian plant with an opioid‐like profile, has been increasingly used in the United States for ...
Rita Kamoua   +4 more
wiley   +1 more source

Economic burden of hidradenitis suppurativa based on healthcare resource utilization: German claims data analysis

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease affecting approximately 0.1% of the German population. Patients with HS require substantial healthcare resource utilization. This study aimed to assess the economic burden associated with HS in Germany.
Falk G. Bechara   +7 more
wiley   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy